Asked by: Rachel Hopkins (Labour - Luton South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how the £95 million investment in dementia clinical (a) trials and (b) innovative research will be allocated across the Mission’s pillars of (i) innovations in biomarkers, data and digital and imaging technologies, (ii) increasing the number and speed of UK-based clinical trials for research into dementia and neurodegeneration and (iii) end-to-end implementation.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Dame Barbara Windsor Dementia Mission was launched in August 2022 with £95 million of Government funding. There is now more than £120 million of committed funding to the mission, which will be invested into three key pillars. The first pillar centres on biomarkers and experimental medicine, and will receive £50 million of the funding for the mission, with the intention of securing match funding from industry partners. As part of this pillar, Innovate UK launched a Small Business Research Initiative competition, with the aim of accelerating innovations in clinical biomarker tools and technologies for dementia, where organisations could apply for a share of £6 million of funding out of the allocated £50 million. These technologies will enable the discovery, validation, and implementation of a suite of decision-enabling biomarkers to help transform clinical trials and precision therapies. The competition closed on 4 September 2023, and the recipients awarded a portion of the £6 million will be announced soon.
The second pillar will focus on clinical trial infrastructure and innovation, with two recently announced initiatives to support its delivery. The first of these initiatives is the National Institute for Health and Care Research’s Dementia-Translational Research Collaboration Trials Network, with almost £50 million of funding over five years. This will expand the United Kingdom’s early phase clinical trial capabilities for dementia, speeding up the development of new treatments. The second initiative is the Clinical Trials Delivery Accelerator, focused on dementia, also named the Dementia Accelerator. This was announced in the Autumn Statement 2023, in response to Lord O’Shaughnessy’s independent review into commercial clinical trials in the UK, with up to £20 million of additional funding.
The third pillar will be focused on end-to-end implementation, specifically on aligning translational research, clinical practice, and regulatory frameworks to prepare health-systems for new dementia medicines. The Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence, NHS England, the Department, the devolved administrations, and the Dame Barbara Windsor Dementia Mission are already working closely together to plan for the implementation of new dementia medicines, should they gain approval in the UK.
Asked by: Kate Osamor (Labour (Co-op) - Edmonton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how the additional £95 million investment in dementia care has been allocated.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Dame Barbara Windsor Dementia Mission was launched in August 2022 with £95 million of Government funding. There is now more than £120 million of committed funding to the mission, which will be invested into three key pillars. The first pillar centres on biomarkers and experimental medicine, and will receive £50 million of the funding for the mission, with the intention of securing match funding from industry partners. As part of this pillar, Innovate UK launched a Small Business Research Initiative competition, with the aim of accelerating innovations in clinical biomarker tools and technologies for dementia, where organisations could apply for a share of £6 million of funding out of the allocated £50 million. These technologies will enable the discovery, validation, and implementation of a suite of decision-enabling biomarkers to help transform clinical trials and precision therapies. The competition closed on 4 September 2023, and the recipients awarded a portion of the £6 million will be announced soon.
The second pillar will focus on clinical trial infrastructure and innovation, with two recently announced initiatives to support its delivery. The first of these initiatives is the National Institute for Health and Care Research’s Dementia-Translational Research Collaboration Trials Network, with almost £50 million of funding over five years. This will expand the United Kingdom’s early phase clinical trial capabilities for dementia, speeding up the development of new treatments. The second initiative is the Clinical Trials Delivery Accelerator, focused on dementia, also named the Dementia Accelerator. This was announced in the Autumn Statement 2023, in response to Lord O’Shaughnessy’s independent review into commercial clinical trials in the UK, with up to £20 million of additional funding.
The third pillar will be focused on end-to-end implementation, specifically on aligning translational research, clinical practice, and regulatory frameworks to prepare health-systems for new dementia medicines. The Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence, NHS England, the Department, the devolved administrations, and the Dame Barbara Windsor Dementia Mission are already working closely together to plan for the implementation of new dementia medicines, should they gain approval in the UK.
Mar. 07 2024
Source Page: Spring Budget puts UK on fast-track to becoming science and technology superpowerFound: This will help cement the institutes leadership in setting research agendas alongside supporting UK business
Nov. 25 2008
Source Page: Office for strategic coordination of health research: chairman's first report, November 2008. 68 p.Found: Office for strategic coordination of health research: chairman's first report, November 2008. 68 p.
Dec. 05 2011
Source Page: Innovation Health and Wealth: Accelerating Adoption and Diffusion in the NHS. 36 p.Found: Innovation Health and Wealth: Accelerating Adoption and Diffusion in the NHS. 36 p.
May. 07 2024
Source Page: Research and Innovation for Development in ASEAN (RIDA)Found: Research and Innovation for Development in ASEAN (RIDA)
Feb. 08 2024
Source Page: What works in international R&I collaboration: evidence reviewFound: and Asia CSSP Climate Science for Service Partnership DBT Department for Business & Trade DFID
Nov. 30 2009
Source Page: Innovation Pass Pilot: A consultation on proposals for an Innovation Pass pilot. 32 p.Found: of Health The Department of Health use the reco mmendations to inform the allocation of funding for
Nov. 23 2023
Source Page: Science, Innovation and Technology backed in Chancellor’s 2023 Autumn StatementFound: Battery Manufacturing Alongside the Department for Business and Trade’s battery strategy, the Chancellor
Mentions:
1: Lucy Powell (LAB - Manchester Central) How is stopping the small boats going? - Speech Link
2: Penny Mordaunt (Con - Portsmouth North) We should be proud of the research that has been done in the UK. - Speech Link
3: Christine Jardine (LD - Edinburgh West) I know that the Minister of State, Department for Business and Trade, the hon. - Speech Link
4: Penny Mordaunt (Con - Portsmouth North) I will ensure that the Department of Health and Social Care has heard what he has said. - Speech Link